• Something wrong with this record ?

Favorable prognostic significance of membranous β-catenin expression and negative prognostic significance of cytoplasmic β-catenin expression in pancreatic cancer

B. Rosova, J. Proks, A. Filipova, D. Hadzi Nikolov, R. Chloupkova, I. Richter, A. Szabo, A. Rozsypalova, R. Matej, B. Melichar, T. Buchler, J. Dvorak

. 2023 ; 70 (6) : 796-803. [pub] -

Language English Country Slovakia

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007881

The aim of this study was to investigate the prognostic significance of membranous β-catenin and cytoplasmic β-catenin expression in pancreatic cancer patients (pts). One hundred pts with histologically verified exocrine pancreatic ductal adenocarcinoma were retrospectively studied. The membranous β-catenin, cytoplasmic β-catenin, and cell nucleus β-catenin expression were immunohistochemically evaluated. The expression of membranous β-catenin was <5% in none of the pts, 5-25% in one patient, 26-50% in 2 pts, 51-75% in 14 pts, and >75% in 81 pts. The expression of cytoplasmic β-catenin was <5% in 34 pts, 5-25% in 42 pts, 26-50% in 18 pts, 51-75% in 3 pts, and >75% in one patient. The expression of β-catenin in the cell nucleus was negative in all pts. At the time of the last follow-up, 21 pts were alive and 79 pts had died. Median OS was 1.3 (0.4-2.3) years in pts with membranous β-catenin expression ≤75% and 1.7 (1.3-2.1) years in pts with membranous β-catenin expression >75% (p=0.045). Median OS was (1.3-2.0) 1.6 years in pts with cytoplasmic β-catenin expression ≤25% and 0.9 (0.5-1.2) years in pts with cytoplasmic β-catenin expression >25% (p=0.040). In the univariate Cox proportional hazard models HR (95% CI) was 0.556 (0.311-0.995) in pts with membranous β-catenin expression >75% (p=0.048) and 2.200 (1.216-3.980) in pts with cytoplasmic β-catenin expression >25% (p=0.009). The present results indicate a favorable prognostic significance of membranous β-catenin expression in pancreatic cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007881
003      
CZ-PrNML
005      
20240423160345.0
007      
ta
008      
240412s2023 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2023_230721N380 $2 doi
035    __
$a (PubMed)38247336
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Rosova, Blanka $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
245    10
$a Favorable prognostic significance of membranous β-catenin expression and negative prognostic significance of cytoplasmic β-catenin expression in pancreatic cancer / $c B. Rosova, J. Proks, A. Filipova, D. Hadzi Nikolov, R. Chloupkova, I. Richter, A. Szabo, A. Rozsypalova, R. Matej, B. Melichar, T. Buchler, J. Dvorak
520    9_
$a The aim of this study was to investigate the prognostic significance of membranous β-catenin and cytoplasmic β-catenin expression in pancreatic cancer patients (pts). One hundred pts with histologically verified exocrine pancreatic ductal adenocarcinoma were retrospectively studied. The membranous β-catenin, cytoplasmic β-catenin, and cell nucleus β-catenin expression were immunohistochemically evaluated. The expression of membranous β-catenin was <5% in none of the pts, 5-25% in one patient, 26-50% in 2 pts, 51-75% in 14 pts, and >75% in 81 pts. The expression of cytoplasmic β-catenin was <5% in 34 pts, 5-25% in 42 pts, 26-50% in 18 pts, 51-75% in 3 pts, and >75% in one patient. The expression of β-catenin in the cell nucleus was negative in all pts. At the time of the last follow-up, 21 pts were alive and 79 pts had died. Median OS was 1.3 (0.4-2.3) years in pts with membranous β-catenin expression ≤75% and 1.7 (1.3-2.1) years in pts with membranous β-catenin expression >75% (p=0.045). Median OS was (1.3-2.0) 1.6 years in pts with cytoplasmic β-catenin expression ≤25% and 0.9 (0.5-1.2) years in pts with cytoplasmic β-catenin expression >25% (p=0.040). In the univariate Cox proportional hazard models HR (95% CI) was 0.556 (0.311-0.995) in pts with membranous β-catenin expression >75% (p=0.048) and 2.200 (1.216-3.980) in pts with cytoplasmic β-catenin expression >25% (p=0.009). The present results indicate a favorable prognostic significance of membranous β-catenin expression in pancreatic cancer.
650    _2
$a lidé $7 D006801
650    12
$a beta-katenin $x genetika $x metabolismus $7 D051176
650    12
$a duktální karcinom slinivky břišní $x diagnóza $x genetika $7 D021441
650    12
$a nádory slinivky břišní $x diagnóza $x genetika $7 D010190
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Proks, Jan $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Filipova, Alzbeta $u Department of Radiobiology, Faculty of Military Health Sciences in Hradec Kralove, University of Defense in Brno, Hradec Kralove, Czech Republic
700    1_
$a Hadzi Nikolov, Dimitar $u Department of Pathology, Regional Hospital, Kolin, Czech Republic
700    1_
$a Chloupkova, Renata $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Richter, Igor $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic $u Department of Oncology, Regional Hospital, Liberec, Czech Republic
700    1_
$a Szabo, Arpad $u Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Rozsypalova, Aneta $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Matej, Radoslav $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic $u Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Dvorak, Josef $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 70, č. 6 (2023), s. 796-803
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38247336 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160341 $b ABA008
999    __
$a ok $b bmc $g 2081721 $s 1217648
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 70 $c 6 $d 796-803 $e - $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options